

Product Name: InVivoMAb Anti-HeV/NiV Glycoprotein G Antibody**Catalog #:** AMRe60099

For research use only.

Summary

Description	Recombinant human monoclonal antibody
Host	Human
Application	ELISA, Neutralization
Reactivity	Hendra virus (isolate Horse/Australia/Hendra/1994), Nipah virus
Conjugation	Unconjugated
Modification	Unmodified
Isotype	IgG1, kappa
Clonality	Monoclonal
Form	Liquid
Concentration	
Storage	Aliquot and store at -20°C (valid for 12 months). Avoid freeze/thaw cycles.
Shipping	Ice bags
Buffer	0.01M PBS, pH 7.4.
Purification	Protein A/G purified from cell culture supernatant.

Application

Dilution Ratio ELISA 1:5000-1:20000

Molecular Weight

Antigen Information

Gene Name	Glycoprotein G
Alternative Names	Glycoprotein G, G
Gene ID	
SwissProt ID	O89343, Q9IH62
Immunogen	

Background

Nipah virus (NiV), a highly pathogenic zoonotic paramyxovirus, mediates host cell entry through the coordinated action of two envelope glycoproteins: the attachment glycoprotein (G), which engages the host cell receptors ephrin-B2 and ephrin-B3, and the fusion glycoprotein (F), which drives membrane fusion following receptor binding. These viral surface proteins, along with

the viral RNA-dependent RNA polymerase (RdRp) complex comprising the nucleoprotein (N), phosphoprotein (P), and large polymerase protein (L), constitute the primary molecular targets for therapeutic intervention and vaccine development. The conserved receptor-binding interface of the G protein and the fusion machinery of the F protein represent particularly attractive targets for neutralizing antibodies and entry inhibitors, while the viral replication machinery offers potential targets for broad-spectrum antiviral compounds targeting paramyxovirus transcription and replication.

Research Area

Microbiology&Infectious Disease